We are wondering the same thing. We have not heard anything other than the plan is to take it slow and make sure that we do the right thing for the business unit. You know, blah,blah,blah.
You saw what happened to Aventis legacy. Do yourself a favor and start looking for a position elsewhere.
Don't expect much help from Genzyme. Two of the four product Genz transplant and oncology has are the only ones needing a sales force. First prod- Plerixafor needs only 20 reps to support it since it only pertains to transplant centers. And second-Clofarabine would compliment Elitek in the per setting. That would make two teams on the Hem side of about 60 total (40 elitek/20 mozobil). The leadership team is scrambling to make a case for their own jobs and trying to pretend that Sanofi needs to keep them. It will only be a matter of a year or less before Sanofi leadership figures this out. They could cut the Genz sales force down to 20 from approx 50 to merge with the current 40 elitek reps. They could cut half (9 down to 4) of the middle managers (RSD's), cut both national sales directors and nearly all of the levels above that. This is just a guess but I would bet a very accurate one. We will see soon.
True, but on the other hand Sanofi could double this sales forces, throw AID, INC. and the assertive sales presentation model ino the mix and really hammer these doctors good. Access would be gone in less than 6 months
Well Well.........What goes around comes around. Today's press release puts the final nail in this failed division. Hey Zimmy, how does it feel to know you'll be w/o a job in a few month??
Sanofi spurs layoff fears with Genzyme restructuring plans June 1, 2011 Soon after Sanofi closed its $20 billion deal to buy Genzyme, CEO Chris Viehbacher made it clear that the storied biotech company would remain a standalone entity, reassuring loyalists by retaining its name and pushing ahead on the biotech's R&D efforts. Now the Boston Globe reports that only a scaled-down version of Genzyme will remain semi-independent as Sanofi absorbs the rest of the company into its big pharma system. Quoting an employee bulletin, reporter Robert Weisman says that New Genzyme will include only its personalized genetic health and multiple sclerosis operations. Oncology, biosurgery, and renal operations will be taken over by other Sanofi units. Genzyme is slated to get a new CEO in the fall to replace Henri Termeer. That job is now being held on an interim basis by Viehbacher. What isn't clear, reports the Globe, is whether the new corporate structure will trigger layoffs, a closely watched issue as Genzyme's 4,500 Boston employees (10,000 worldwide) anxiously await word of Sanofi's plans. In every significant buyout of the past several years, though, an M&A deal was the catalyst for major job cuts as the acquiring pharma companies hunted out any potential synergies to make the buyout work on the bottom line.
Before the buyout and as it was taking place, Genzyme employees posted here asking questions, as they were led to believe by SA that Genzyme would remain an intact entity, etc. Any/all SA employees knew, without a doubt, that this was an outright lie. Genzyme employees, based on the fact that that company operated above board with respect for employees and without lying to them, found it difficult to comprehend that things would change once the takeover was complete. Well, the proof is in the pudding and the pudding is about to be served. Sorry to all Genzyme employees who have been slapped with SA's ugly reality.
